rct
    2022

    Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women

    Fukamizu Y, Uchida Y, Shigekawa A

    Published in Scientific Reports

    Key Findings

    NMN 1250 mg/day for four weeks was well tolerated with no clinically meaningful adverse changes in laboratory or vital measures.

    Conclusions

    Short-term safety appears acceptable.

    Limitations

    Four weeks only; no long-term data.

    Supplements Studied

    NMN
    Compound

    NMN 1250 mg/day for four weeks was well tolerated with no clinically meaningful adverse changes.

    Vitamin B3
    Vitamin

    NMN 1250 mg/day for four weeks was well tolerated with no clinically meaningful adverse changes in laboratory or vital measures.

    Study Details

    Year:2022
    Sample Size:31
    Duration:4 weeks
    Quality Score:6/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.